[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546297":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":44,"responsibleParty":75,"collaborators":26,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":26,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":26,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Comparator: 1 Placebo","PLACEBO_COMPARATOR","Half of the patients will receive PO placebo",[13],"Drug: BRC-002 Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Experimental: Active","EXPERIMENTAL","Drug: BRC-002 (High Cannabidiol Botanical Extract) 100 mg\u002FmL",[19],"Drug: BRC-002",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","BRC-002","BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\\\u003C.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"BRC-002 Placebo","Oral solution of mono-, di-, and triglycerides",[9],[32],{"name":33,"affiliation":34,"role":35},"Fadel Zeidan, PhD","UC San Diego","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","858-246-8341","fzeidan@health.ucsd.edu",{"name":42,"role":38,"phone":39,"phoneExt":26,"email":43},"Yasmeen Esshaki, MS","yesshaki@health.ucsd.edu",[45,66],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Altman Clinical and Translational Research Institute","RECRUITING","La Jolla","California","92093","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-117.2742,32.84727,{"lat":57,"lon":56},[60,64],{"name":33,"role":38,"phone":61,"phoneExt":62,"email":63},"858-246-2028","62028","zeidanlab@ucsd.edu",{"name":65,"role":38,"phone":61,"phoneExt":62,"email":43},"Yasmeen Esshaki, MA",{"facility":5,"status":47,"city":67,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"San Diego",{"type":54,"coordinates":69},[70,71],-117.16472,32.71571,{"lat":71,"lon":70},[74],{"name":33,"role":38,"phone":61,"phoneExt":62,"email":40},{"type":35,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Fadel Zeidan","Associate Professor","100546297","phase-1-the-effects-and-mechanisms-of-a-high-cbd-cannabis-extract-brc-002-for-the-treatment-of-pain-and-health-in-complex-regional-pain-syndrome-100546297",false,"NCT06393101","The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome","A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Are between 21-75 years old\n3. Ability to communicate in English\n4. Volunteers with no previous medical history (e.g., cardiac or pulmonary disease)\n5. Are not currently using any type of cannabis, including hemp or CBD\n6. Currently 30 days cannabis free\n7. Participants with ongoing CRPS \\[Type 1 or Type 2)\\] for at least 3 months prior to participation (medical record confirmed)\n8. Agrees not to use cannabis, including hemp or CBD, outside of the study during participation in the study\n9. Agrees not to use opioids or barbiturates during participation in the study\n\nExclusion Criteria:\n\n1. Fail cannabis screening\n2. Active pulmonary disease\n3. Allergy or past adverse effects or negative past experiences from cannabis\n4. Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone prior to study session 1 or session 2\n5. Any significant illness, including cardiovascular disease, diabetes, renal and liver disease\n6. Any current or history of an immunocompromising disease or condition (such as lupus, psoriasis, multiple sclerosis, etc.)\n7. Any current or history of neurologic conditions, including Parkinson disease, dementia, cognitive impairment, history of seizure disorder, and history of traumatic brain injury\u002Fhead injury\n8. Participant meets DSM-V criteria for current major psychiatric illness, such as bipolar disorder, major depression, psychosis, substance use disorder, or schizophrenia\n9. Any current or history of suicidal ideation or attempt\n10. Patients with clinically significant laboratory abnormalities","ALL","21 Years","75 Years",{"count":89,"type":90},52,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","The aim of this trial is to determine the potential effects and mechanisms of cannabinoid-induced pain relief in complex regional pain syndrome (CRPS). Multiple psychophysical approaches will be conducted in conjunction with psychological and inflammatory marker testing to determine if and how cannabinoids produce stabilized improvement in CRPS-related pain and comorbidities.\n\nThe trial consisted of a pre-treatment screening period, six-week treatment period and a two-week follow-up.",[96],"Complex Regional Pain Syndrome",[96,98,99,100],"CRPS","Cannabis","Pain","2024-06-05",{"date":103,"type":104},"2024-06-07","ACTUAL",{"date":106,"type":90},"2024-06-01",{"date":108,"type":90},"2029-06-01",{"name":5,"class":6},2]